logo

Search

Login | Create Account

oncology


Categories

Blood Breast cancer Cancer care Childhood cancers End-of-life care Endocrine GI cancer GU cancer Head and neck cancer Lung cancer Medicines Medicopolitical Melanoma Podcasts Radiation oncology Research Risk Factors Sarcoma

Other

Conferences

Specialties


Cardiology Dermatology Endocrinology Gastroenterology Haematology Neurology Oncology Respiratory Rheumatology

General


Contact Us About Us Website Disclaimer Privacy Policy Terms & Conditions

©2022 the limbic

logo

COSA 2018

Tuesday 13th - Thursday 15th November 2018

Cancer care

COSA 2018: An oncologist’s experience of prescribing medical cannabis

An oncologist involved in medical cannabis trials in Australia says prescribing it is challenging on many levels, but has become easier over the last two years. Speaking at COSA 2018 in Perth, Dr Rob Zielinski who practices in Orange, NSW, said oncologists...

An oncologist involved in medical cannabis trials in Australia says prescribing it is challenging on many levels, but has become...


End-of-life care

Best case/worst case – is there a better way to explain survival times to patients?

Patients with advanced cancers invariably overestimate their likely survival time and may benefit from ‘best case’ and ‘worst case’ scenarios from their oncologist, research presented at COSA 2018 in Perth suggests. An analysis of 67 patients with cancers taking part in...

Patients with advanced cancers invariably overestimate their likely survival time and may benefit from ‘best case’ and ‘worst case’ scenarios...


Lung cancer

Quest for mesothelioma treatments centres on genomic vulnerabilities

The lack of breakthrough treatments for mesothelioma in recent years is because the cancer is not associated with a single genetic mutation that can be targeted, a UK expert told COSA 2018 in Perth. But the successful genome mapping of mesothelioma...

The lack of breakthrough treatments for mesothelioma in recent years is because the cancer is not associated with a single...


Cancel
Cancel